🇺🇸 Niacin/ Laropiprant in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 12

Most-reported reactions

1. Blood Glucose Increased — 2 reports (16.67%)
2. Drug-Induced Liver Injury — 2 reports (16.67%)
3. Adverse Event — 1 report (8.33%)
4. Bronchitis — 1 report (8.33%)
5. Cardiac Failure Congestive — 1 report (8.33%)
6. Chest Pain — 1 report (8.33%)
7. Cough — 1 report (8.33%)
8. Death — 1 report (8.33%)
9. Defaecation Urgency — 1 report (8.33%)
10. Flushing — 1 report (8.33%)

Source database →

Frequently asked questions

Is Niacin/ Laropiprant approved in United States?

Niacin/ Laropiprant does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Niacin/ Laropiprant in United States?

Ludwig-Maximilians - University of Munich is the originator. The local marketing authorisation holder may differ — check the official source linked above.